for the China PEACE Collaborative Group Background--China is experiencing a marked increase in ST-segment elevation myocardial infarction hospitalizations, with 30% occurring among women and higher risk of in-hospital death in relatively younger age groups (<70). Yet, little is known about sex differences in ST-segment elevation myocardial infarction presentation and management.
A s part of China's epidemiologic transition to higher rates of noncommunicable diseases, women, like men, are experiencing a rapid increase in the incidence of acute myocardial infarction (AMI) and AMI-related mortality, 1 as seen in other low-and middle-income countries. 2 In addition, the China Patient-centered Evaluative Assessment of Cardiac Events (PEACE) study demonstrated sex differences in mortality with women at higher risk of death in younger age groups. 3 Yet, much less is known about whether sex differences in clinical profiles and care quality differ between men and women and, if so, whether these differences are explained by age, and how they change over time. Understanding sex differences in the clinical presentation and quality of care for high-impact conditions like AMI is instrumental to the prioritization of resources for quality improvement programs. A recognition of sex differences in the treatment of myocardial infarction in the late 1990s and early 2000s [4] [5] [6] in the United States led to national campaigns 7 and female-specific guidelines. [8] [9] [10] Subsequently, sex gaps in care have narrowed over time. 5, 11 Previous studies in China demonstrate similar sex differences in treatment of comorbidities and outcomes. 3, [12] [13] [14] However, these studies were generally limited to single sites or centers located predominantly in urban areas and examined single points in time, warranting a national perspective on sex differences in clinical presentation and quality of care in China. 12, 13 Moreover, given that women are older than men at the time of an AMI, 3, 15 it remains unknown whether these differences could be explained by age or how sex-based differences have changed over the last decade during improved access and healthcare quality in China. 16 To provide insights into differences in patient characteristics and quality of care over time between men and women, we analyzed data from the China PEACE Retrospective AMI Study, 17 which included a random nationally representative sample of patients with AMI from 63 urban and 99 rural hospitals across China in 2001, 2006, and 2011. We have previously shown women in the younger age group had higher in-hospital mortality. In this study, our primary aim is to investigate sex differences in the presenting characteristics and quality of care of patients with ST-segment elevation myocardial infarction (STEMI), whether these differences could be accounted for by age, and to examine temporal trends.
Methods

Study Design
The objectives, scope, and purpose of the China PEACE Retrospective AMI Study have been described previously. 
Study Sample
Only patients with a definite discharge diagnosis of STEMI (with or without prior cardiovascular disease) were eligible for inclusion in this study. The diagnosis of STEMI was determined by the combination of clinical discharge diagnosis terms and ECG results. The type of AMI was validated by review of ECG from randomly selected records by a cardiologist not involved in data abstraction, and there was a 94.7% concordance in the selected cases (Table S1 ). We excluded all patients whose STEMI occurred during the course of the hospitalization and those who were transferred in, transferred out, and were discharged alive in the first 24 hours of admission ( Figure S1 ).
Data Collection and Measures
We collected data by central abstraction of medical charts with use of standardized data definitions, including patient characteristics (age, cardiovascular risk factors, clinical characteristics on presentation, and treatments) and hospital-level characteristics (acuity level, teaching status, percutaneous coronary intervention [PCI] capability). We compared time from symptom onset to admission between men and women, which included both prehospital delay and time from arrival to admission. Admission was used to track the time of presentation because we lacked information about time to presentation at the hospital. We evaluated the use of treatments recommended by the 2010 National Guideline for STEMI, 18 which are consistent with 2007 U.S. guidelines. 19 Rates of utilization were assessed only in patients considered to be ideal for the treatment, defined as patients without accepted contraindications. Criteria identifying ideal candidates for guideline-concordant therapies are detailed in Data S1. For the calculation of rates of diagnostic catheterization and PCI, we restricted our study group to patients admitted to facilities capable of performing PCI.
Statistical Analysis
To estimate nationally representative rates of hospitals admission in men and women for each study year, we applied weights proportional to the inverse sampling fraction of hospitals within each stratum and the sampling fraction of patients within each hospital, to account for differences in the sampling fraction for each period. Patient characteristics and treatments were compared between women and men, both overall and across the 3 study years (2001, 2006, and 2011) . Categorical and continuous variables were summarized by percentages and medians (interquartile range), respectively, and compared using the v 2 tests and Student t tests, respectively. To examine trends across the different study periods for each sex, we used the Mann-Kendall test for continuous variables and the Cochran-Armitage test for categorical variables. We investigated the association between sex and the prevalence of cardiovascular risk factors, adjusted for age in logistic regression models. To examine the association between sex and treatment received, we also adjusted for age and other baseline characteristics as listed in Table 1 using multivariable logistic models. We included the 2-way interaction term sex9year in the regression model to assess whether sex differences in presenting characteristics and treatment varied by study year. All statistical analyses were performed using SAS software (version 9.2, SAS Institute, Cary, NC).
Results
Study Sample
We sampled 18 631 cases, from which 18 110 (97.2%) had available records. We excluded 6645 cases that did not meet inclusion criteria, resulting in a study sample of 11, 986 patients with STEMI ( Figure S1 ). 
Patients Characteristics
From 2001 to 2011, the median age of patients increased from 68 to 72 years in women (P trend <0.001) but remained stable in men (63 years in 2011) (P trend =0.48). The proportions of men and women aged ≥80 years old significantly increased over time (Figure 1 ). The prevalence of cardiovascular risk factors increased over time for both women and men. Women had a higher prevalence of hypertension, diabetes mellitus, and coronary heart disease in each time period (P<0.001 for all comparisons) ( Table 1) . Similar findings were also found in the age-adjusted results ( Figure 2 ). In addition, sex differences in the prevalence of hypertension increased from 2001 to 2011, with women having a higher prevalence. However, sex differences in the prevalence of diabetes remained stable. Although there was no significant sex difference in those with a low-density lipoprotein cholesterol >130 mg/dL in 2001, this risk factor was more prevalent in women in later time periods (Figure 2 ). Women were hospitalized less often in tertiary care hospitals and hospitals with the capacity to perform PCI. Women were consistently were more likely to have systolic blood pressure over 140 mm Hg and heart rate over 100 bpm. Comparing 2001 Comparing , 2006 , and 2011, sex differences in heart rate >100 bpm increased, yet differences in the presence of systolic blood pressure measurements did not change. Although there were significant sex differences in the time interval of >12 hours between symptom onset and admission time in 2001, since 2006 delays in presentation were comparable between women and men ( Figure 3) . The age-adjusted results showed that there was no sex difference in chest discomfort in 2001 and 2006, but not 2011.
Treatment Among Ideal Candidates
The proportion of ideal patients for aspirin, clopidogrel, b-blocker, angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker, and statin treatments remained unchanged over time in both sex groups (Table S2) . Although the proportion of women ideal for reperfusion therapy increased significantly over the last decade (from 35.7% in 2001 to 43.0% in 2011, P trend =0.001), they remained less likely than men (48.2%) to be ideal patients for reperfusion therapy in 2011.
Overall, differences in treatment were consistently observed over the study period. The absolute differences between men and women receiving fibrinolytic therapy, primary PCI, or any reperfusion therapy were 6.7%, 5.5%, and 13.2% in 2011, respectively. In addition, any coronary angiography and nonprimary PCI were performed less commonly during initial AMI hospitalization in women in all time periods. Fewer women received aspirin or clopidogrel within 24 hours of admission (Table 2) . After adjusting for age and other baseline characteristics, women without contraindications to treatment were significantly less likely to receive reperfusion therapy, coronary angiography, and nonprimary PCI in all time periods (Table S3) . No significant sex differences were observed in the administration of other examined medications, including b-blocker, angiotensin-converting enzyme inhibitor/ angiotensin II receptor blocker, and statin. Between 2001 and 2011, sex differences in treatment persisted, and in some cases widened. In particular, sex differences in the utilization of primary PCI increased ( Figure 4 ).
Discussion
In this large, national study in China of hospitalization for STEMI, we found marked sex differences in clinical profiles and quality of care. Women, who experienced a slightly higher increase (4.2-fold versus 3.9-fold) in STEMI over the study period, were older, had greater comorbidities, and were less likely to be ideal patients for many evidence-based therapies. Among ideal patients, women were significantly less likely to receive a revascularization strategy (including fibrinolysis or cardiac catheterization with or without PCI), even after accounting for differences in clinical profiles. These sexbased differences in patient characteristics and hospital care did not change significantly over the past decade, underscoring the need to specifically address these findings with quality improvement efforts. We had previously shown in the China PEACE study that the risk of mortality was age dependent and most pronounced among younger women (<70 years of age) with STEMI, even after accounting for differences in clinical presentation and treatments. 3 However, we had not investigated temporal trends in sex differences as they relate to patient characteristics and receipt of evidence-based therapies in STEMI. We found that even after adjusting for age, with the exception of smoking, a predominantly male activity in China, 20 risk factors including greater age, diabetes, hypertension, and dyslipidemia were more common in women presenting with STEMI. These are consistent with prior national and international studies. 21, 22 The clinical presentation of women differed from men. Indeed, half of the women in our study presented outside the time window for reperfusion therapy, which is consistent over the last decade. However, we did observe a decrease in the delay to admission among women, and sex differences in the time interval of >12 hours between symptom onset and admission time disappeared since 2006, which might partly be due to improved healthcare accessibility for women in China. 23 While the quality of care improved for both men and women, significant sex gaps exist and have not improved over time. Significantly fewer women received a reperfusion strategy, even when they presented promptly for treatment. Additionally, among patients deemed to be ideal candidates, women were less likely than men to receive aspirin and clopidogrel. Sex differences in treatment response have not been supported by the literature; rather, prior studies indicate that both women and men derive similar reductions in morbidity and mortality with the prescriptions of aspirin, clopidogrel, and with invasive cardiac procedures, 4 and guidelines do not recommend differential use of these therapies based upon sex. The disparities in care identified in this study require full-scale investigation into clinical decision-making and targeted efforts to diminish such disparities.
The rising burden of modifiable cardiovascular risk factors among women will require local and national efforts to advance primary and secondary prevention strategies; such efforts may need to directly target women at high risk of heart attack. The marked underutilization of coronary catheterization and reperfusion therapy should prompt quality improvement efforts to ensure that the evidence-based management of STEMI is rigorously applied in patients of both sexes. 24 In the interim, large-scale educational initiatives targeting women should be implemented in both pre-hospital and inhospital settings to increase women's and their health providers' awareness of cardiovascular disease and recognition of symptoms of AMI, 25 which has been proven to be effective in the Go Red for Women campaign, which was initiated in the United States. 25 Ultimately, dispelling myths (or old assumptions) and improving awareness is difficult and will require innovative, multipronged efforts.
Limitations
The results of our study should be interpreted with consideration of several limitations. First, residual confounding of measured or unmeasured variables might affect the observed results. However, we accounted for traditional clinical factors common among risk models predicting early mortality. Second, given that relatively few patients underwent a cardiac catheterization, we were not able to adjust our analysis to account for the severity and extent of coronary artery diseases that might contribute to the sex differences in mortality. 26 However, these data are not typically included in risk-adjusted models, and it is not clear that anatomy would affect in-hospital mortality differently in men and women.
Conclusions
In a large, nationally representative observational study in China, women hospitalized with STEMI were older, had greater delays in care seeking, more comorbidities, and worse disease severity than men. Moreover, women were less likely to be candidates for, and less likely to receive, evidencebased therapies as compared with men. These disparities have changed little over the past decade despite large-scale efforts to increase access and quality. These findings underscore the need for improved systems to ensure the prompt diagnosis and use of evidence-based treatments for women with STEMI, particularly with respect to reperfusion therapies.
